Invitrogen SuperScript II Reverse Transcriptase is a genetically engineered MMLV reverse transcriptase (RT) with reduced RNase H activity and increased thermal stability compared to wild-type MMLV RT. Mutations in the RNase H domain of the enzyme eliminate degradation of the RNA during first-strand cDNA synthesis, which results in higher yields of full-length cDNA.

SuperScript reverse transcriptases are the most highly trusted and widely used RTs with over 50,000 citations, reviews, and publications to date. The enzyme is purified to near homogeneity from E. coli containing the modified pol gene of Moloney Murine Leukemia Virus.

Features of SuperScript II Reverse Transcriptase include:
• High cDNA yields and more full-length product
• Generation of cDNA up to 12.3 kb
• First-strand cDNA synthesis at higher temperatures than conventional MMLV RT

Note: The latest member of the SuperScript RT family, SuperScript IV Reverse Transcriptase, features enhanced thermostability, processivity, yields, and performance with any RNA samples, including those of suboptimal purity or integrity.